Please try another search
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Name | Age | Since | Title |
---|---|---|---|
Omar J. Jimenez | 62 | 2024 | Director |
Ryan L. Smith | 41 | 2024 | Director |
Jagdeep Nanchahal | - | - | Co-Founder & Chairman of Clinical Advisory Board |
Blair Jordan | - | 2024 | Lead Independent Director |
Lawrence Steinman | 76 | 2019 | Co-Founder & Executive Chairman |
Sallie Lamb | - | 2022 | Member of Scientific Advisory Board |
James N. Woody | 82 | 2020 | CEO & Director |
Kevin J. Tracey | - | 2022 | Member of Scientific Advisory Board |
Irene Tracey | - | 2022 | Member of Scientific Advisory Board |
Chas Bountra | - | 2022 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review